336 related articles for article (PubMed ID: 32059024)
1. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
2. Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.
Bristol JA; Brand J; Ohashi M; Eichelberg MR; Casco A; Nelson SE; Hayes M; Romero-Masters JC; Baiu DC; Gumperz JE; Johannsen EC; Dinh HQ; Kenney SC
PLoS Pathog; 2022 Apr; 18(4):e1010453. PubMed ID: 35472072
[TBL] [Abstract][Full Text] [Related]
3. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
Bristol JA; Djavadian R; Albright ER; Coleman CB; Ohashi M; Hayes M; Romero-Masters JC; Barlow EA; Farrell PJ; Rochford R; Kalejta RF; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Jul; 14(7):e1007179. PubMed ID: 30052684
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
5. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
6. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
7. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
9. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
Jung YJ; Choi H; Kim H; Lee SK
J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
[TBL] [Abstract][Full Text] [Related]
11. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression.
Li Y; Webster-Cyriaque J; Tomlinson CC; Yohe M; Kenney S
J Virol; 2004 Apr; 78(8):4197-206. PubMed ID: 15047835
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
Gradoville L; Kwa D; El-Guindy A; Miller G
J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
16. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
Ma SD; Yu X; Mertz JE; Gumperz JE; Reinheim E; Zhou Y; Tang W; Burlingham WJ; Gulley ML; Kenney SC
J Virol; 2012 Aug; 86(15):7976-87. PubMed ID: 22623780
[TBL] [Abstract][Full Text] [Related]
17. The ZIIR element of the Epstein-Barr virus BZLF1 promoter plays a central role in establishment and maintenance of viral latency.
Yu X; McCarthy PJ; Lim HJ; Iempridee T; Kraus RJ; Gorlen DA; Mertz JE
J Virol; 2011 May; 85(10):5081-90. PubMed ID: 21389123
[TBL] [Abstract][Full Text] [Related]
18. Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus.
Gutiérrez MI; Ibrahim MM; Dale JK; Greiner TC; Straus SE; Bhatia K
J Natl Cancer Inst; 2002 Dec; 94(23):1757-63. PubMed ID: 12464647
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter.
Sun CC; Thorley-Lawson DA
J Virol; 2007 Dec; 81(24):13566-77. PubMed ID: 17898050
[TBL] [Abstract][Full Text] [Related]
20. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]